JP Morgan Maintains Overweight on TG Therapeutics, Lowers Price Target to $22
Portfolio Pulse from richadhand@benzinga.com
JP Morgan analyst Eric Joseph has maintained an Overweight rating on TG Therapeutics (NASDAQ:TGTX) but lowered the price target from $34 to $22.
August 07, 2023 | 3:58 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan has maintained an Overweight rating on TG Therapeutics but lowered the price target from $34 to $22.
The news is directly related to TG Therapeutics. While the Overweight rating indicates a positive outlook, the lowering of the price target may have a neutral to slightly negative impact on the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100